Abstract
Heme oxygenase-1 (HO-1) is central to the regulation of oxidative injury. The role of increased HO-1 expression and Heme oxygenase (HO) activity in mitigating the detrimental side effect of diabetes is examined. A review of the mechanism(s) of action is included. This may lead to the development of pharmacological and genetic approaches to mitigate the clinical complications associated with the progression of diabetes and obesity.
Keywords: Diabetes, Carbon monoxide, bilirubin, HO-1, Inflamation, TNF, IL-1, adiponectin
Current Pharmaceutical Design
Title: Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Volume: 14 Issue: 5
Author(s): N. G. Abraham, P. L. Tsenovoy, J. McClung and G. S. Drummond
Affiliation:
Keywords: Diabetes, Carbon monoxide, bilirubin, HO-1, Inflamation, TNF, IL-1, adiponectin
Abstract: Heme oxygenase-1 (HO-1) is central to the regulation of oxidative injury. The role of increased HO-1 expression and Heme oxygenase (HO) activity in mitigating the detrimental side effect of diabetes is examined. A review of the mechanism(s) of action is included. This may lead to the development of pharmacological and genetic approaches to mitigate the clinical complications associated with the progression of diabetes and obesity.
Export Options
About this article
Cite this article as:
Abraham G. N., Tsenovoy L. P., McClung J. and Drummond S. G., Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity, Current Pharmaceutical Design 2008; 14 (5) . https://dx.doi.org/10.2174/138161208783597371
DOI https://dx.doi.org/10.2174/138161208783597371 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease
Current Vascular Pharmacology Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Augmentation of Creatine in the Heart
Mini-Reviews in Medicinal Chemistry Mesenchymal Stem Cells: A Good Candidate for Restenosis Therapy?
Current Vascular Pharmacology Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain
Current Alzheimer Research The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design Angiotensin Type 1 Receptor Blockers in Heart Failure
Current Drug Targets Characterizing the Bi-Subunit Type IB DNA Topoisomerase of Leishmania Parasites; a Novel Scenario for Drug Intervention in Trypanosomatids
Current Drug Targets Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?
Current Vascular Pharmacology COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Electrochemical-Based Biosensors: New Diagnosis Platforms for Cardiovascular Disease
Current Medicinal Chemistry Oxidative Stress, Endothelial Dysfunction and Atherosclerosis
Current Pharmaceutical Design Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future
Current Stem Cell Research & Therapy Meet Our Regional Editor
Current Vascular Pharmacology Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure
Current Vascular Pharmacology Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets